Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Innovent Biologics, Inc (IVBXF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Innovent Biologics, Inc $9.18, price $12.80, upside -28.3%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
IB
Some data
Oct 3, 2026
Some data
Oct 3, 2026
Innovent Biologics, Inc
IVBXF · USOvervalued / MonitorQuality growthQuality is not strong enough to offset the price risk.
!Fair value $9.18 · Overvalued (−28.3%)
!Quality 52/100
✓Healthy Growth (revenue 5y +27.0 %/yr)
!Thin margins · 6.2% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 34/100
!Evidence only medium, so the estimate is less certain
Watch Innovent Biologics, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $2.30 – $15.01 · fair‑value band $6.80 – $12.60 · the $12.80 price screens above the $9.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Company profile
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally.
Show more
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Stock analysis
Innovent Biologics, Inc (IVBXF) currently trades at $12.80, while our model-based Fair Value estimate is $9.18, 28.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $26.71 per share, and 5 of the 23 models we run sit above the $12.80 price.
Bear case: the Asset-Based group reads lowest at $1.12, and 18 of the 23 models stay below the price. Evidence for this calculation is medium.
Scenario range: $6.80 (bear) to $12.60 (bull), the price of $12.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Innovent Biologics, Inc reported revenue of 12.7B CNY in FY2025 versus 4.3B CNY in FY2021, a compound +31.3%/yr. Reported net income was 793M CNY in FY2025.
Key figures
Market cap $22.3B · P/E ratio 182.9 · P/S ratio 11.4 · EPS (TTM) $0.0700 · Net margin 6.2% · Return on equity 5.0% · Return on assets (EBIT) −8.2% · Operating margin −0.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 41% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −28%, IVBXF screens richer than that median.
Fair Value models
Bear $6.80
Fair Value $9.18
Bull $12.60
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0529 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV
$2.77
$3.02
$3.23
74
FCF DCF
$14.92
$22.72
$47.55
73
5Y EBITDA Exit
$6.80
$9.26
$14.01
73
All 23 models by family
DCF Models
FCF DCF
$14.92
$22.72
$47.55
73
Owner Earnings
$2.38
$3.72
$6.54
72
5Y Revenue Exit
$6.29
$8.23
$12.15
71
5Y EBITDA Exit
$6.80
$9.26
$14.01
73
5Y P/E Exit
$5.89
$8.60
$11.77
69
10Y Revenue Exit
$8.81
$13.83
$15.80
66
10Y EBITDA Exit
$9.25
$14.92
$23.52
65
10Y P/E Exit
$8.59
$12.98
$19.02
61
Earnings-Based
Graham-Dodd
$0.4600
$3.23
$4.54
61
Lynch FV
$1.67
$2.39
$3.10
59
PEG = 1.0
$1.67
$2.39
$3.10
55
EPV
$2.77
$3.02
$3.23
74
Multiples
P/E Multiple
$1.13
$1.50
$1.88
63
P/S Multiple
$0.8700
$1.16
$1.45
58
P/B Multiple
$0.8700
$1.16
$1.45
55
EV/EBIT
$3.48
$4.20
$4.92
66
EV/EBITDA
$3.65
$4.42
$5.19
67
EV/Revenue
$2.86
$3.53
$4.19
54
Asset-Based
NCAV (Graham)
$0.8300
$1.12
$1.67
54
Growth DCF
Growth DCF
$14.11
$26.71
$47.35
73
Economic Profit
Residual Income
$1.25
$1.24
$1.29
68
ROIC Compounder
$3.18
$4.11
$5.35
70
Growth Earnings
Growth-Adj P/E
$2.22
$3.17
$4.12
65
Notify me when IVBXF reaches fair value
Put IVBXF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
52/100
Of which business quality 57 · Market factors (momentum, volatility) 51
Profitability
32
Margins and returns on capital today
Quality Growth
71
Are margins and returns improving?
Cashflow
99
Earnings quality: real cash, not paper profit
Fin. Strength
74
Balance sheet, leverage, solvency risk
Investment
27
Disciplined investing over empire-building
Low Volatility
50
Calm price path (market factor)
Momentum
53
Price trend over the last 3–12 months (market factor)
52W Momentum
51
Distance to the 52-week high (market factor)
Net Issuance
19
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+34.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.0%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+94.3%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.5% (2020) → 15.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+20.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −2.3% a year for the price and +18.9% for the forecasts.
Forecast 2026 (sales)+47.5%
Forecast 2027 (sales)+18.1%
Projected 2028 (sales)+16.1%
Projected 2029 (sales)+14.1%
Projected 2030 (sales)+12.1%
Recent news
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
- Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Im
- Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
- 2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche
Compare Innovent Biologics, Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Innovent Biologics, Inc (IVBXF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $9.18 versus a price of $12.80, about −28% upside (overvalued).
What is the fair value of IVBXF?
Our model-based fair value for Innovent Biologics, Inc is $9.18 (as of Oct 3, 2026), built from audited fundamentals. The current price: $12.80.
What is the quality score of IVBXF?
Innovent Biologics, Inc has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Innovent Biologics, Inc (IVBXF)?
Our model-based price target is the fair value of $9.18 (as of Oct 3, 2026) from 23 valuation models. Cautious scenario $6.80, optimistic scenario $12.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Innovent Biologics, Inc stock forecast for 2026?
Our models put fair value at $9.18, about −28% upside versus a price of $12.80 (overvalued). Cautious scenario $6.80, optimistic scenario $12.60. The calculation is refreshed regularly with new filings.
What is the revenue of Innovent Biologics, Inc (IVBXF)?
Innovent Biologics, Inc reported trailing-twelve-month revenue of about 13.0B CNY (latest available figure, as of Oct 3, 2026).
What growth is priced into Innovent Biologics, Inc (IVBXF)?
For today's price to be fair in a discounted-cash-flow model, Innovent Biologics, Inc would have to grow free cash flow by -0.7 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +27.0 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of IVBXF use?
Our models discount Innovent Biologics, Inc at 8.1 %: a base by market capitalisation (large), damped by beta 0.21, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Innovent Biologics, Inc that is -0.7 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Innovent Biologics, Inc (IVBXF) delivered so far?
Over the past 5 years revenue at Innovent Biologics, Inc grew +27.0 % a year. The price currently implies -0.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Innovent Biologics, Inc (IVBXF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Innovent Biologics, Inc (-0.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Innovent Biologics, Inc (IVBXF)?
The free-cash-flow yield on the price is 6.23 %: that much free cash flow Innovent Biologics, Inc produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Innovent Biologics, Inc (IVBXF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Innovent Biologics, Inc it is $9.18 per share (as of Oct 3, 2026), against a price of $12.80. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Innovent Biologics, Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, IVBXF trades above its calculated fair value: price $12.80, fair value $9.18, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IVBXF?
No. The price is what the market pays today ($12.80); the fair value is what the company's own numbers justify ($9.18). For Innovent Biologics, Inc the two are $3.62 per share apart. That gap is exactly why we show both numbers side by side.
How much is Innovent Biologics, Inc worth?
The market values Innovent Biologics, Inc at about $22.3B (market capitalisation, as of Oct 3, 2026). Per share that is $12.80; our models calculate a fair value of $9.18 per share.
What do the bullish and bearish scenarios say about IVBXF?
Our models span a range for Innovent Biologics, Inc: cautious scenario $6.80, base $9.18, optimistic $12.60 per share (as of Oct 3, 2026, price $12.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IVBXF?
Innovent Biologics, Inc trades at a price-to-earnings ratio of 182.9 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $9.18 is built from several models across several years. Other multiples: PEG 1.7.
What is the PEG ratio of IVBXF?
The PEG ratio of Innovent Biologics, Inc is 1.75 (P/E divided by earnings growth, as of Oct 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Innovent Biologics, Inc (IVBXF)?
Balance-sheet figures for Innovent Biologics, Inc (as of Oct 3, 2026): return on equity 5.0%, debt of 0.10 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is IVBXF from its 52-week high?
Innovent Biologics, Inc trades at $12.80, about 15% below its 52-week high of $15.01 and 41% above the low of $9.10 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $9.18 is for.
Which stocks are comparable to Innovent Biologics, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Innovent Biologics, Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $12.80, calculated fair value $9.18 (−28%), Quality Score 52/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IVBXF calculated?
We run Innovent Biologics, Inc through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $9.18, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Innovent Biologics, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Innovent Biologics, Inc (IVBXF)?
The closing price on Oct 2, 2026 was $12.80. Our model-based fair value is $9.18, about −28% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Innovent Biologics, Inc right now?
Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($6.80 to $12.60) leaves room in how you read the outcome.
Key figures of Innovent Biologics, Inc
How large is the market capitalisation of Innovent Biologics, Inc (IVBXF)?
The market capitalisation of Innovent Biologics, Inc is $22.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Innovent Biologics, Inc (IVBXF)?
The price-to-sales ratio of Innovent Biologics, Inc is 11.4 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Innovent Biologics, Inc (IVBXF)?
Earnings per share at Innovent Biologics, Inc are $0.0700 (price ÷ EPS = P/E 182.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Innovent Biologics, Inc (IVBXF)?
The net margin of Innovent Biologics, Inc is 6.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Innovent Biologics, Inc (IVBXF)?
The return on equity (ROE) of Innovent Biologics, Inc is 5.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Innovent Biologics, Inc (IVBXF)?
On an EBIT basis the return on assets of Innovent Biologics, Inc is −8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Innovent Biologics, Inc (IVBXF)?
The operating margin of Innovent Biologics, Inc is −0.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Innovent Biologics, Inc (IVBXF)?
Revenue at Innovent Biologics, Inc is growing +29.6% versus a year earlier (3y avg +40.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Innovent Biologics, Inc (IVBXF) hold?
Innovent Biologics, Inc holds more cash than debt, 14.5B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Innovent Biologics, Inc in the live analysis
One click puts Innovent Biologics, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.